Last updated: 2026-09-16 10:31:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Silo Pharma, Inc. (SILO) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.92, with a market capitalisation of $3.63M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.91 to $15.15. This page covers its latest market performance, valuation, price trends and company information.
$3.63M | |
$1.92 | |
$186.68 | |
$1.91 | |
$1.94 | |
1.65K | |
194.37K | |
-- | |
$15.15 | |
$1.91 | |
-- | |
-- |
Silo Pharma, Inc. (SILO) is trading at $1.92 in pre-market trading as of 2026-09-16 09:52:00, down 1.03% ($0.02) from the previous close of $1.94
Pre-market trading shows how investors are pricing SILO before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Silo Pharma, Inc. (SILO) moved from $2.40 to $1.92, representing a decline of 20.00% ($0.48).
The stock traded between $1.91 and $2.50 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 31.78 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.1%
SILO is currently trading at $1.92, placing it 0.1% of the way from its 52-week low of $1.91 to its 52-week high of $15.15. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 3 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Silo Pharma, Inc. (SILO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.